A clinical trial in the United States moves through four defined phases, plus an ongoing post-market surveillance stage, before a treatment reaches the market and stays there. Phase 1 asks whether a drug is safe. Phase 2 asks whether it works. Phase 3 asks whether it works better than what patients already have access to, at a scale large enough to trust. Phase 4 keeps watching after approval. The path is long: drug development from first-in-human dosing to FDA approval typically runs 10 to 15 years, and only a small share of drugs that enter Phase 1, commonly cited around 12%, ever reach approval, per the Biotechnology Innovation Organization's industry-wide clinical development success-rate analysis. Each phase carries its own regulatory purpose and its own recruitment problem. This explainer takes a marketing lens to that timeline: what each phase actually tests, and where patient recruitment fits into a process built primarily around safety and evidence.
Quick answer:
- Phase 1: Tests safety in a small group, typically 20 to 100 healthy volunteers or patients, over roughly a year.
- Phase 2: Tests whether the treatment works and starts tracking side effects, in 100 to 300 participants, over one to two years.
- Phase 3: Tests the treatment against the current standard of care at scale, in hundreds to thousands of participants, over one to four years. This is the largest and longest phase, and the one that produces the primary evidence regulators review.
- Phase 4: Monitors the approved treatment in the general patient population, often thousands of people, for as long as it stays on the market.
What Is A Clinical Trial, And Why Is It Split Into Phases?
A clinical trial is a research study that tests how a drug, device, or treatment behaves in humans, run under a specific protocol, an assigned sponsor, and oversight from an Institutional Review Board (IRB) at every participating site. The U.S. Food and Drug Administration (FDA) requires any human study of an investigational product to proceed under an Investigational New Drug (IND) application, which sets the ground rules for testing before a single participant is ever dosed. Every registered trial is listed publicly on ClinicalTrials.gov, the National Institutes of Health's (NIH) database, so patients, physicians, and researchers can see what is being studied, where, and by whom.
The phase structure exists because drug development is fundamentally a risk-reduction exercise. Rather than testing a new compound on thousands of patients at once, regulators require sponsors to answer one question at a time: Is it safe? Does it work? Does it work better than existing options, reliably, across a broad and varied population? Each phase must clear its own bar, using its own control group, its own informed consent process, and, in most later-stage trials, randomization and blinding, before the FDA authorizes the next phase. A trial that fails to demonstrate safety in Phase 1 never advances to Phase 2, no matter how promising the underlying science looks. That structure protects patients first, but it also means recruitment needs, timelines, and marketing strategy differ meaningfully at every stage.
Clinical Trial Phases At A Glance
The table below summarizes what each phase tests, how many participants it typically requires, how long it usually runs, and where recruitment marketing becomes a relevant part of the process.
Phase 1 Clinical Trials: Testing For Safety
Phase 1 answers one question: is this treatment safe enough to keep testing? Sponsors typically enroll 20 to 100 participants, sometimes healthy volunteers, sometimes patients with the target condition when the treatment is too toxic to give to a healthy population, as is common in oncology. Dosing starts low and escalates in controlled steps while researchers watch for adverse events, track how the body absorbs, processes, and clears the compound, and establish a maximum tolerated dose. A Phase 1 trial usually runs about a year, though oncology Phase 1 studies that combine dose escalation with early efficacy signals can run longer than that.
This is the phase with the least public-facing recruitment activity of the four, because the participant pool is small, tightly screened against a narrow eligibility profile, and often drawn from a handful of academic medical centers that already run early-phase research as part of their standing operations.
Where Marketing Enters Phase 1
Recruitment marketing at Phase 1 looks nothing like a typical demand-generation campaign. Volume is not the goal; precision is. Sponsors need a small number of highly specific participants, so any recruitment activity tends to run on a narrow radius around one or a handful of specialist sites, with screening criteria tight enough that most inbound interest will be disqualified before ever reaching a study coordinator. Messaging tends to be clinical and direct rather than motivational, because the audience is often already engaged with a research site or referred in by a treating physician.
This is general industry framing, not a claim of first-hand campaign experience. Because Phase 1 recruitment is so site-dependent and low-volume, most performance-marketing agencies, Brighter Click included, do not carry meaningful campaign data at this stage. Sponsors researching Phase 1 recruitment support should expect that stage to run through the trial site's own referral network and academic partnerships more than through paid acquisition channels.
Phase 2 Clinical Trials: Testing If It Works
Phase 2 answers a different question: does the treatment actually work, and what does it cost the body to find out? Participant counts grow to roughly 100 to 300, the study population narrows to people who actually have the target condition, and researchers begin tracking efficacy signals alongside safety, often for the first time against a placebo or an active control group. Phase 2 trials typically run one to two years, and this is usually the first phase where a treatment fails on efficacy or feasibility grounds if it does not show the effect sponsors are looking for.
Where Marketing Enters Phase 2
Recruitment opens up meaningfully at Phase 2. The participant pool is still condition-specific, but it is large enough that a single academic medical center rarely covers it alone, so sponsors start running geo-targeted recruitment across multiple sites and, in some cases, multiple metro areas. This is also the first point in the process where general cost-per-lead benchmarks become genuinely useful, because volume is high enough to produce reliable numbers rather than a handful of anecdotal data points.
Published clinical-trial recruitment data shows how much that cost varies by condition: Adams Clinical reported per-lead costs of roughly $780 for an anxiety trial, $1,400 for an Alzheimer's trial, and $1,750 for a depression trial, based on anonymized patient acquisition data. The spread makes a simple point that matters for anyone planning a Phase 2 budget: condition, not phase alone, drives most of the cost variance in trial recruitment, because some conditions have smaller eligible populations, more competing trials chasing the same patients, or more stigma attached to self-identifying as a candidate.
Phase 3 Clinical Trials: Proving It At Scale
Phase 3 answers the question regulators care about most: does this treatment perform better than the current standard of care, reliably, across a population large enough to trust the result? Trials at this stage enroll anywhere from several hundred to several thousand participants, usually across many sites, often using randomization and double-blind design so neither participants nor investigators know who received the treatment versus the control. Phase 3 is the longest and most expensive phase, typically running one to four years, and it produces the primary evidence the FDA reviews when deciding whether to approve a treatment.
It is also the phase where recruitment marketing does the most work, because Phase 3 studies need volume and speed at the same time: enough qualified participants, fast enough that the trial does not stall out waiting on enrollment while site costs keep accruing.
Where Marketing Enters Phase 3
This is the stage where a dedicated recruitment marketing strategy has the clearest, most measurable impact, and it is where Brighter Click has direct campaign data to draw on. Adams Clinical's recruitment work identified four recurring participant motivators that show up across condition types: Hope, Symptoms, Memory Loss, and Availability. Framing creative around whichever motivator fits the specific condition, rather than running one generic message across every trial, changed cost efficiency meaningfully. The memory-loss angle, used for an Alzheimer's-related trial, produced a cost per lead of $27.96, well below the broader per-condition benchmarks cited above.
Creative format mattered almost as much as message. Testing video, GIF, and static ad formats against the same audience produced a clear ladder: video at $38.40 per lead, GIF at $39.49, and static at $41.63. The gap between formats is real but modest, which suggests format functions as a secondary lever behind message and targeting, not the primary driver of cost.
Two more mechanics separate Phase 3 recruitment from earlier phases. First, targeting narrows to the zip-code level around each trial site rather than a broad metro radius, because participants generally will not travel far for a multi-visit study that can run for months. Second, creative and landing pages get batched and submitted for IRB approval in groups rather than one at a time, since every recruitment asset a Phase 3 trial runs needs sign-off before it can go live, and a multi-site trial can mean dozens of near-identical assets moving through review at once. Planning how a recruitment budget scales across a multi-site Phase 3 trial is a question sponsors and CROs typically work through together, since site count and geography drive most of the spend.
Phase 4 Clinical Trials: Watching After Approval
Phase 4 begins after the FDA has approved a treatment, so it is not part of the pre-approval trial process at all; it is ongoing surveillance of a drug that is already on the market. Sponsors, and sometimes the FDA directly, continue monitoring the treatment in a much larger and more diverse population than any Phase 1 through 3 trial could enroll, often thousands of patients, to catch rare side effects, long-term risks, or drug interactions that only surface at scale over years of real-world use. This is also referred to as post-marketing surveillance, and it answers a common question directly: post-marketing surveillance falls under Phase 4, not Phase 3.
Where Marketing Enters Phase 4
Marketing's role here is limited, and it looks different from the recruitment work in Phases 1 through 3. Phase 4 activity sits closer to pharmacovigilance reporting and patient registry enrollment than to acquisition marketing: sponsors need patients and physicians to report outcomes and adverse events over time, not to sign up for a controlled study with defined visits and endpoints. Brighter Click has no campaign data specific to Phase 4 registry or surveillance work, and this section is included for completeness rather than as a service claim. Sponsors researching Phase 4 support should expect that need to sit closer to patient communications, registry management, or long-term pharmacovigilance programs than to the recruitment marketing playbook that applies earlier in the process.
How Long Does The Whole Process Take, From Phase 1 To Approval?
Start to finish, moving a drug from Phase 1 through FDA approval commonly takes 10 to 15 years, a figure widely cited across industry and regulatory sources. That timeline breaks down roughly as follows: preclinical research and IND filing before human testing even begins, then around a year for Phase 1, one to two years for Phase 2, one to four years for Phase 3, and finally FDA review of the New Drug Application, which typically adds another year or more before a decision. Attrition is steep at every step along the way: most compounds that enter Phase 1 never reach approval, and the industry-wide success rate from first-in-human testing through approval is commonly cited around 12%, per the Biotechnology Innovation Organization's cross-industry analysis of clinical development outcomes.
Almost none of that timeline is something a sponsor can compress. Regulatory review periods, minimum follow-up windows, and the sheer number of participants required at Phase 3 are fixed by protocol and by FDA requirement, not by budget. What is not fixed, and what varies enormously between sponsors running trials of the same size, is how fast each phase fills its enrollment target. A Phase 3 trial that struggles to recruit can add months or years onto an otherwise fixed regulatory calendar, and every month of delayed enrollment is a month of trial-site overhead and, for time-sensitive conditions, a month patients wait for access to a treatment that might help them. Recruitment speed is one of the only variables inside a sponsor's control, which is why it gets disproportionate attention from CROs and sponsors alike once a trial reaches Phase 2 or Phase 3.
Accelerate Your Enrollment Before the Funding Runway Closes
Most variables in clinical drug development are locked by protocol and regulatory mandate. What remains variable, and poses the greatest threat to your trial’s capital runway, is enrollment velocity.
When strict inclusion/exclusion criteria stall recruitment at Phase 2 or Phase 3, site overhead continues to accrue against fixed grant or sponsor budgets. Relying on passive site referrals risks exhausting your funding window before your cohort targets are met.
If your trial is actively recruiting or preparing for Phase 2 or Phase 3 and you cannot afford enrollment delays, let’s talk.
Brighter Click designs high-precision, IRB-compliant digital recruitment campaigns built to find qualified, protocol-matched participants around your trial sites at scale.
Frequently Asked Questions
How many phases does a clinical trial have?
Most clinical trials for a new drug or treatment move through four phases, commonly labeled Phase 1 through Phase 4, plus a preclinical research stage before any human testing begins. Some sponsors also run an optional, much smaller Phase 0 study ahead of Phase 1, though it is far less common.
What are the phases of a clinical trial called?
They are named numerically: Phase 1 (safety), Phase 2 (efficacy and side effects), Phase 3 (efficacy at scale versus the standard of care), and Phase 4 (post-approval surveillance). There is no separate common name for each phase beyond its number, though "post-marketing surveillance" is often used interchangeably with Phase 4.
What is an FDA clinical trial phase?
An FDA clinical trial phase is one of the defined stages of human testing the FDA requires under an Investigational New Drug (IND) application before a treatment can be approved and marketed. Each phase has its own participant size, endpoints, and evidence standard, and a sponsor cannot move to the next phase without FDA authorization based on the results of the previous one.
Is there a Phase 0 clinical trial?
Yes, though it is optional and far less common than Phases 1 through 4. Phase 0 trials use very small doses, sometimes called microdosing, in a handful of participants to gather early pharmacokinetic data before a sponsor commits to a full Phase 1 program. Not every drug development effort includes one.
What does "post-marketing surveillance" mean, and which phase is it?
Post-marketing surveillance is the ongoing safety monitoring of a treatment after it has already received FDA approval and become available to the general public. It falls under Phase 4, and it exists because rare side effects or long-term risks often only appear once a drug is used by a much larger and more varied population than any pre-approval trial could enroll.
How is Phase 3 different from Phase 2?
Phase 2 asks whether a treatment works and begins tracking side effects in a few hundred participants at most. Phase 3 asks the same question at a scale large enough to compare the treatment directly against the current standard of care, typically across hundreds to thousands of participants and multiple trial sites, and its results are what regulators primarily rely on when deciding whether to approve a treatment.
Every phase above runs on a regulatory clock no sponsor can move. The one lever that stays flexible from Phase 2 onward is how fast each site fills its enrollment target, and that is a marketing and operations problem as much as a clinical one. For CROs and sponsors planning recruitment ahead of an upcoming phase, budget and timeline questions tend to surface earliest around Phase 2 and Phase 3, where participant volume and geography start driving cost.
